HeartMate III is the next-generation continuous flow left ventricular assist device (:LVAD). It is based on fully magnetically levitated technology in order to reduce adverse event rates through ...

HeartMate III is a next-generation continuous flow left ventricular assist device (:LVAD) based on fully magnetically levitated technology. This technology helps in reducing adverse event rates ...

Manufacturer and marketer of medical devices used for mechanical circulatory support, Thoratec Corp.THOR, recently announced that the first HeartMate III implant has been conducted via ...

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final ...

FDA has granted Thoratec Corp. permission to enlarge its pivotal trial for the next-generation HeartMate III left ventricular assist system (LVAS). This gives the company the ability to enroll a ...

A surgical team in Toronto has successfully implanted a novel mechanical device, the HeartMate IIITM, into a patient with advanced heart failure. This is the first time this procedure has been ...

Sharp Memorial Hospital has become the first hospital on the West Coast — and only the sixth in the country — to implant an investigational mechanical heart pump as part of a nationwide clinical trial ...

PLEASANTON, Calif., June 27, 2014 /PRNewswire/ --Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing ...

Thoratec shed almost one-third of its value after reporting abysmal second quarter earnings. The advanced heart failure device company attributed most of the miss to a New England Journal of Medicine ...

Abbott has issued a recall for select HeartMate mobile power units used with its HeartMate3 and HeartMate III left-ventricular assist systems due to risk of sudden power loss that could lead to ...

Thoratec Corp.THOR recently announced the start of patient enrollment in the SHIELD II U.S. clinical trial, which aims at exploring the use of HeartMate PHP in patients undergoing high-risk ...

The deal helps round out St. Jude's menu of heart failure devices and services. Chris Newmarker St. Jude Medical will spend $3.4 billion to acquire Thoratec, a major LVAS player on the U.S. market.